To clarify the mechanisms of interaction between adenosine A 1 receptor (A1-R) and adenosine A 2 receptor (A2-R) on neurotransmitter release, this study determined the functional interactions among adenosine receptors (AD-Rs), voltage-sensitive Ca 2ϩ channels (VSCCs), protein kinases (PKs), and synaptic proteins [N-ethylmaleimide-sensitive factor (NSF) attachment protein (SNAP) receptors] on hippocampal serotonin release using in vivo microdialysis in freely moving rat. Basal serotonin release was regulated by two functional complexes: N-type VSCC (N-VSCC)/calcium-phospholipid-dependent protein kinase (PKC)/syntaxin (major pathway) and P-type VSCC (P-VSCC)/cyclic AMP-dependent protein kinase (PKA)/synaptobrevin (minor pathway). However, K ϩ -evoked serotonin release was regulated by N-VSCC/PKC/syntaxin (minor pathway) and P-VSCC/PKA/synaptobrevin (major pathway). A1-R antagonists increased basal serotonin release, which was reduced by inhibitors of N-VSCC, PKC, and syntaxin predominantly and by inhibitors of PKA and synaptobrevin weakly, but was not affected by P-VSCC inhibitor. In the presence of A1-R antagonist, A2-R agonists increased basal serotonin release, which was inhibited by inhibitors of P-VSCC, PKA, and synaptobrevin predominantly and reduced by inhibitors of N-VSCC, PKC, and syntaxin weakly. Under the condition of activation of adenylate cyclase in the absence of A1-R antagonists, A2-R agonists increased basal serotonin release. A1-R antagonist and A2-R agonist enhanced K ϩ -evoked serotonin release, which was inhibited by inhibitors of P-VSCC, PKA, and synaptobrevin predominantly. These results suggest that an activation of A1-R suppresses serotonin release via inhibition of both N-VSCC/ PKC/syntaxin and P-VSCC/PKA/synaptobrevin pathways, and an activation of A2-R stimulates serotonin release via enhancement of the P-VSCC/PKA/synaptobrevin pathway. Therefore, PKA activity plays an important role in the interaction between A1-R and A2-R on hippocampal serotonin release.
Adenosine is a potent modulator of synaptic transmission at various synapses (Linden, 1994) . Recently, four major classes of adenosine receptor (AD-R) subtypes have been pharmacologically identified and cloned (Linden, 1994; Olah and Stiles, 1995) . Many lines of evidence suggest that an activation of adenosine A 1 receptor (A1-R) suppresses neurotransmitter release (Barraco and Stefano, 1990; Zetterstrom and Fillenz, 1990; Ambrosio et al., 1997; Okada et al., 1997 Okada et al., , 1999a Satoh et al., 1997; Ribeiro, 1999; Von Lubitz, 1999) primarily by presynaptic mechanisms, including the voltage-sensitive Ca 2ϩ channel (VSCC) and the K ϩ channel (Yawo and Chuhma, 1993; Ambrosio et al., 1997; Wu and Saggau, 1997; Wu et al., 1999) . Activation of the adenosine A 2 receptor (A2-R) enhances the evoked release of various neurotransmitters (Popoli et al., 1995; Ambrosio et al., 1997; Satoh et al., 1997 ) that may involve P-type VSCC (P-VSCC) (Umemiya and Berger, 1994; Satoh et al., 1997) . It has been recognized that the response to adenosine is a balance between A1-R and A2-R activations because monoamine release is reduced and enhanced by agonists of A1-R and A2-R, respectively. The stimulatory effects of A2-R can be masked by activation of A1-R (Correia- de-Sa et al., 1996; Okada et al., 1997 Okada et al., , 1999a . However, the mechanisms of this interaction between A1-R and A2-R have not been clarified yet. A mechanistic model for neurotransmitter release, known as the soluble [N-ethylmaleimide-sensitive factor (NSF) attachment protein (SNAP) receptor] (SNARE) hypothesis, proposes that vesicle membrane SNAREs bind to cognate proteins on the target membrane SNARE to form complexes that are recognized and dissociated by the general membrane-trafficking factors ␣-SNAP and NSF (Sollner et al., 1993; Sudhof, 1995) . After arrival of an action potential at presynaptic terminals and the resulting entry of Ca 2ϩ via VSCC, the local level of Ca 2ϩ rises abruptly to submillimolar levels (Sollner et al., 1993; Sudhof, 1995; Sheng et al., 1998) . Biophysical and pharmacological analyses have led to the identification of N-type VSCC (N-VSCC) and P-VSCC as being involved in neurotransmitter release in the mammalian CNS (Dunlap et al., 1995; Bergquist et al., 1998; Okada et al., 1998a,b; Wu et al., 1998 Wu et al., , 1999 . These findings are consistent with observations that neurotransmitter release at many central synapses is blocked by N-VSCC or P-VSCC inhibitors (Takahashi and Momiyama, 1993; Wheeler et al., 1994; Bergquist et al., 1998; Okada et al., 1998a; Wu et al., 1998) . Second-messenger-activated protein kinases (PKs), including calcium-phospholipid-dependent protein kinase (PKC) and cyclic AMP-dependent protein kinase (PKA), regulate neurotransmission via modulation of the inter-actions of SNARE apparatus (Sudhof, 1995; Zamponi et al., 1997; Kaneko et al., 1998; Hamid et al., 1999; Turner et al., 1999; Yoshihara et al., 1999) . Moreover, our previous study (Okada et al., 1998a) demonstrated that the basal and K ϩ -evoked striatal dopamine release was predominantly regulated by N-VSCC and P-VSCC, respectively. Together with previous evidence that clarifies the mechanisms of interaction between A1-R and A2-R on neurotransmitter release in spontaneous and depolarization states, this study determined the effects of AD-Rs, VSCCs, PKs, and SNARE complexes on hippocampal basal and K ϩ -evoked serotonin releases using in vivo microdialysis in freely moving rats.
MATERIALS AND METHODS
All experiments described in this report were performed in accordance with the specifications of the Animal Research Committee of Hirosaki University and met the Guideline Animal E xperimentation of Hirosaki University. Male Wistar rats (C lea, Tokyo, Japan), weighing 250 -300 gm, were housed under conditions of constant temperature (22 Ϯ 2°C) with a 12 hr light /dark cycle.
Microdial ysis system preparation. Each rat was placed in a stereotaxic frame and kept under halothane anesthesia (1.5% mixture of halothane and O 2 with N 2 O). Before the microdialysis probe was inserted, each rat was pretreated with a microinf usion of 0.3 l of modified Ringer's solution (MRS) with or without 0.03, 0.3, or 3 ng of botulinum toxins (BoN Ts) (C apogna et al., 1997; Pierce and Kalivas, 1997) because the molecular weight of BoN Ts (Ͼ100,000) is beyond the cutoff for diff usion through the dialysis membrane. A concentric I-type dialysis probe (0.22 mm diameter; 3 mm exposed membrane) (Eicom, Kyoto, Japan) was implanted in the hippocampus (anterior, Ϫ5.8 mm; lateral, 4.8 mm; ventral, Ϫ4.0 mm, relative to bregma), and the perf usion experiments were started 18 hr after the rats had recovered from anesthesia (Okada et al., 1998a) . The perf usion rate was always 1 l /min. The MRS contained (in mM): 145 Na ϩ , 2.7 K ϩ , 1.2 C a 2ϩ , 1.0 Mg 2ϩ , and 154.4 C l Ϫ ; the pH was adjusted to 7.40 with 2 mM phosphate buffer and 1.1 mM Tris buffer (Okada et al., 1998b) . To study the effects of an increase in the extracellular K ϩ level (K ϩ -evoked stimulation) on the hippocampal extracellular serotonin level, MRS containing 50 mM K ϩ (HK MRS) was perf used for 20 min (Okada et al., 1998a) . The ionic composition was modified, and isotonicity was maintained by an equimolar decrease of Na ϩ (Okada et al., 1998b) . Each hippocampal dialysate was injected every 10 min into a high-performance liquid chromatography (HPLC).
HPLC system preparation. The HPLC system used for determination of the extracellular serotonin levels was equipped with an electrochemical detector (ECD-300; Eicom) with pump (EP-30; Eicom) and a graphite carbon electrode set at ϩ450 mV (vs an Ag /AgC l reference electrode). The analytical column (100 ϫ 1.5 mm, internal diameter) was packed with Mightysil RP-18 (particle size, 5 m) (gift from Kanto Chemicals, Tokyo, Japan) by Masis Inc. (Hirosaki, Japan). The mobile phase was composed of 0.1 M phosphate buffer containing 20% (v/ v) methanol, 900 mg / l octansulfonic sodium, and 50 mg / l EDTA-2Na; the final pH was 5.9, and the column temperature was maintained at 25°C with the flow rate set at 200 l /min (Okada et al., 1998a) .
Chemical agents. The summary of chemical agents used in this study is described in Table 1 . The chemical agents were adenosine (Nacalai Tesque, Osaka, Japan); caffeine (Nacalai Tesque); the A1-R agonist, 2-chloro-N 6 -cyclopentyladenosine (CCPA; Research Biochemicals, Natick, MA); the A1-R antagonist, 8-cyclopentyl-1,3-dimethylxanthine (CPT; Research Biochemicals); the A2-R agonist, N 6 -[2-(3,5-dimethoxyphenyl)-2-(methylphenyl)-ethyl]adenosine (PD125944; Research Biochemicals); the A2-R antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX; Research Biochemicals); the N-VSCC inhibitor, -conotoxin GVIA (GVIA; Peptide Institute, Osaka, Japan); the P-VSCC inhibitor, -agatoxin IVA (IVA; Peptide Institute); the PKA inhibitor, H-89 (Calbiochem, San Diego, CA); the PKC activator, phorbol 12-myristate 13-acetate (PMA; Nacalai Tesque); the PKC inhibitor, chelerythrine (CHR; Calbiochem); the adenylate cyclase activator, forskolin (Nacalai Tesque); the SNAP-25 inhibitor, BoNT type A (BoNT/A; Calbiochem); the synaptobrevin inhibitor, BoNT/B (Calbiochem); and the syntaxin inhibitor, BoNT/C (Calbiochem).
Drug administration. All rats were pretreated with a microinf usion of 0.3 l of MRS with or without 0.03, 0.3, or 3 ng of BoN Ts before insertion of the dialysis probe. Perf usion was commenced with MRS. At least 6 hr after the perf usion started, the hippocampal extracellular serotonin level was measured. When the coefficients of variation of hippocampal extracellular serotonin level reached Ͻ5% over 60 min (stabilization) (Okada et al., 1998a) , control data were obtained for an additional 60 min; then the perf usion medium (MRS) was switched to MRS containing the various agents (pretreatment period).
To study the effects of target agents on basal hippocampal serotonin release, after confirming that the hippocampal extracellular serotonin level had reached a plateau (stabilization), we switched the perf usion 
3,7-Dimethyl-1-propargylxanthine
(1) Takahashi and Momiyama, 1993; (2) Chijiwa et al., 1990 ; (3) Herbert et al., 1990 ; (4) Barg et al., 1992 ; (5) Oishi and Yamaguchi, 1994; (6) Liu and Heckman, 1998 ; (7) Seamon et al., 1981; (8) Niemann et al., 1995; (9) Williams, 1991. medium for pretreatment to the same perf usion medium added to the target agent for 120 min.
To study the effects of target agents on hippocampal K ϩ -evoked serotonin release, after the confirming stabilization, we switched the pretreatment perf usion medium to HK MRS containing the same agents for 20 min (K ϩ -evoked stimulation). After this K ϩ -evoked stimulation, the perf usion medium was switched to the pretreatment perf usion medium for an additional 100 min.
RESULTS
The mean serotonin level in hippocampal perfusate during the spontaneous stage (basal serotonin level) was 3.6 Ϯ 0.4 fmol/10 l (10 min). In the pilot study, perfusion with MRS containing tetrodotoxin (TTX) and Ca 2ϩ -depletion MRS decreased the extracellular serotonin level to Ͻ0.7 fmol/10 l (data not shown). Furthermore, an elevation of the K ϩ level in the perfusate from 2.7 to 50 mM increased the extracellular serotonin levels (K ϩ -evoked release, 13.7 Ϯ 1.6 fmol/10 l) (see Fig. 3A ). Therefore, these experiments demonstrate that under the microdialysis conditions that are presently used, the serotonin levels (basal serotonin release) in hippocampal perfusates were primarily of neuronal origin because the extracellular serotonin level was TTXsensitive, Ca 2ϩ -dependent, and K ϩ -sensitive (Westerink et al., 1989) .
Effects of VSCCs, PKs, and SNAREs on basal serotonin release
The perfusion with GVIA and IVA reduced the hippocampal basal serotonin release in a concentration-dependent manner ( p Ͻ 0.01) (Figs. 1 A, 2 A) , and the inhibitory effect of GVIA was more predominant than that of IVA ( p Ͻ 0.01) (Fig. 2 A) . The perfusion with CHR and H-89 reduced the basal serotonin release in a concentration-dependent manner ( p Ͻ 0.01) (Figs. 1 B, 2 B), and the inhibitory effect of CHR was more predominant than that of H-89 ( p Ͻ 0.05) (Fig. 2 B) . The perfusion with PMA and forskolin increased the extracellular serotonin level in a 
Effects of VSCCs, PKs, and SNAREs on hippocampal K ؉ -evoked serotonin releases
Preperfusion with GVIA and IVA reduced the K ϩ -evoked serotonin release in a concentration-dependent manner ( p Ͻ 0.01) (Figs. 3A, 4A), and the inhibitory effect of IVA was more predominant than that of GVIA ( p Ͻ 0.01) (Fig. 4 A). Preperfusion with CHR and H-89 reduced the K ϩ -evoked serotonin release in a concentration-dependent manner ( p Ͻ 0.01) (Figs. 3B, 4B), and the inhibitory effect of H-89 was more predominant than that of CHR ( p Ͻ 0.01) (Fig. 4 B) . Preperfusion with PMA and forskolin increased the K ϩ -evoked serotonin release in a concentrationdependent manner ( p Ͻ 0.01) (Figs. 3C, 4C), and this stimulatory effect of forskolin was more predominant than that of PMA ( p Ͻ 0.01) (Fig. 4C ). The microinfusion of BoNT/B and BoNT/C reduced the K ϩ -evoked serotonin release in a concentrationdependent manner ( p Ͻ 0.01) (Figs. 3D, 4D ). BoNT/A decreased the K ϩ -evoked serotonin release weakly ( p Ͻ 0.05), but this inhibition was not concentration-dependent (data not shown). The inhibitory effects of BoNT/B were more predominant than those of BoNT/A and BoNT/C ( p Ͻ 0.05) (Fig. 4 D) .
Effects of VSCC inhibitors and BoNTs on PK activatorinduced serotonin releases
The 10 M PMA-induced elevation of the extracellular serotonin level was decreased by perfusion with 1 M GVIA ( p Ͻ 0.01) but was not affected by perfusion with 1 M IVA (Fig. 5A ), whereas the 10 M forskolin-induced elevation of extracellular serotonin level was decreased by perfusion with 1 M IVA ( p Ͻ 0.01) but was not affected by perfusion with 1 M GVIA (Fig. 5B) . The 10 M PMA-induced elevation of the extracellular serotonin level was decreased by microinfusion of 0.3 ng of BoNT/C ( p Ͻ 0.01) but was not affected by that of BoNT/B (Fig. 5A ), whereas the 10 M forskolin-induced elevation of the extracellular serotonin level was decreased by 0.3 ng of BoNT/B ( p Ͻ 0.01) but was not affected by BoNT/C (Fig. 5B) .
The 10 M PMA-induced elevation of K ϩ -evoked serotonin release was reduced by perfusion with 1 M GVIA ( p Ͻ 0.01) but was not affected by perfusion with 1 M IVA (Fig. 5C ), whereas the 10 M forskolin-induced elevation of K ϩ -evoked serotonin release was reduced by perfusion with 1 M IVA ( p Ͻ 0.01) but was not affected by perfusion with 1 M GVIA (Fig. 5D) . The 10 M PMA-induced elevation of K ϩ -evoked serotonin release was decreased by microinfusion of 0.3 ng of BoNT/C ( p Ͻ 0.05) but was not affected by that of BoNT/B (Fig. 5C ), whereas the 10 M forskolin-induced elevation of K ϩ -evoked serotonin release was decreased by microinfusion of 0.3 ng of BoNT/B ( p Ͻ 0.01) but was not affected by microinfusion of 0.3 ng of BoNT/C (Fig. 5D ).
Effect of interaction between VSCCs and SNAREs on basal and K

؉ -evoked serotonin releases
The microinfusion of 0.3 ng of BoNT/C and BoNT/B as well as perfusion with 1 M GVIA and IVA reduced basal and K ϩ -evoked serotonin releases (Fig. 6A,B) . However, under the condition of cleavage of syntaxin and synaptobrevin with pretreatment of 0.3 ng of BoNT/C and BoNT/B, 1 M GVIA and IVA, respectively, could not affect basal serotonin release (Fig. 6 A) . Similar to basal release under the condition of cleavage of syntaxin and synaptobrevin with pretreatment of 0.3 ng of BoNT/C and BoNT/B, 1 M GVIA and IVA, respectively, did not affect K ϩ -evoked serotonin release (Fig. 6 B) .
Effects of AD-R subtypes on basal serotonin release
Adenosine and CCPA decreased the basal serotonin release in a concentration-dependent manner ( p Ͻ 0.01), whereas both caffeine and CPT increased it in a concentration-dependent manner ( p Ͻ 0.01) (Fig. 7 A, B) . Neither PD125944 nor DMPX affected the extracellular serotonin level (Fig. 7 A, B) . Under the condition of A1-R blockade by 10 M CPT, adenosine and PD125944 increased the basal serotonin release in a concentrationdependent manner ( p Ͻ 0.01), whereas caffeine and DMPX decreased it in a concentration-dependent manner ( p Ͻ 0.01) (Fig. 7C,D) . Effect of interaction between A1-R subtypes as well as VSCCs, PKs, and SNAREs on basal serotonin release The elevation of basal serotonin release induced by both 10 M PMA and forskolin was inhibited by perfusion with 0.1 M CCPA ( p Ͻ 0.01) (Fig. 8 A, B) . The stimulatory effect of 10 M CPT on the basal serotonin release was inhibited by perfusion with 1 M GVIA ( p Ͻ 0.01), 1 M CHR ( p Ͻ 0.01), and 1 M H-89 ( p Ͻ 0.05) but was not affected by perfusion with 1 M IVA (Fig.  9 A, B) . Microinfusion of 0.3 ng of both BoNT/B ( p Ͻ 0.05) and BoNT/C ( p Ͻ 0.01) decreased the elevation of basal serotonin release induced by perfusion with 10 M CPT (Fig. 9C) . (Fig. 10 A, B) . The inhibitory effects of 1 M IVA and 10 M H-89 on the action of 10 M PD125944 were more predominant than those of 1 M GVIA and 10 M CHR ( p Ͻ 0.01), respectively ( Fig. 10 A, B) . The stimulatory effect of perfusion with 10 M PD125944 on the basal serotonin release was decreased by microinfusion of 0.3 ng of BoNT/B ( p Ͻ 0.01) and BoNT/C ( p Ͻ 0.05) (Fig. 10C) . The inhibitory effect of BoNT/B on the action of PD125944 was more predominant than that of BoNT/C ( p Ͻ 0.01) (Fig. 10C) .
Effect of interaction between A2-R agonist as well as
Effect of interaction between AD-R subtypes as well as VSCCs, PKs, and SNAREs on K ؉ -evoked serotonin release Perfusion with both 10 M CPT and PD125944 enhanced the K ϩ -evoked serotonin release in a concentration-dependent manner ( p Ͻ 0.01), whereas perfusion with both 0.1 M CCPA and 10 M DMPX reduced it in a concentration-dependent manner ( p Ͻ 0.01) (Fig. 11 A, B) . The stimulatory effect of perfusion with 10 M CPT on the K ϩ -evoked serotonin release was inhibited by perfusion with 1 M IVA ( p Ͻ 0.01), 10 M CHR ( p Ͻ 0.05), and 10 M H-89 ( p Ͻ 0.01) but was not affected by perfusion with 1 M GVIA (Fig. 12 A) . The stimulatory effect of perfusion with 10 M PD125944 on the K ϩ -evoked serotonin release was inhibited by perfusion with 1 M IVA ( p Ͻ 0.01) and 1 M H-89 ( p Ͻ 0.01), but was not affected by perfusion with 1 M GVIA or 1 M CHR (Fig. 12 B) . The stimulatory effect of perfusion with 10 M CPT on the K ϩ -evoked serotonin release was inhibited by microinfusion of 0.3 ng of BoNT/B ( p Ͻ 0.01) and BoNT/C ( p Ͻ 0.05) (Fig. 12 A) . The stimulatory effect of perfusion with 10 M PD125944 on the K ϩ -evoked serotonin release was inhibited by microinfusion of 0.3 ng of BoNT/B ( p Ͻ 0.01) and BoNT/C ( p Ͻ 0.05) (Fig. 12 B) .
Effect of interaction between A2-R agents and forskolin on basal and K
؉ -evoked serotonin release Neither 10 M PD125944 nor DMPX affected the basal serotonin release; however, preperfusion with 10 M forskolin produced both the stimulatory effects of PD125944 ( p Ͻ 0.01) and the inhibitory effects of DMPX ( p Ͻ 0.01) on basal serotonin release in the absence of A1-R antagonist (Fig. 13A) . The stimulatory Figure 6 . Effect of interaction between VSCC inhibitors and BoNTs on basal ( A) and K ϩ -evoked ( B) serotonin release. The ordinates indicate the mean Ϯ SD (n ϭ 6) of extracellular serotonin level ( fmol/10 l ). After the microinfusion with or without 0.3 ng of BoNT/B and BoNT/C, the perfusion medium was switched from MRS to MRS without (Control ) or with 1 M GVIA or 1 M IVA. After confirmation of the stabilization of basal release, the perfusion medium was switched from the same MRS to HKMRS containing the same agents for 20 min. The mean values obtained with the control (no treatment with VSCC inhibitor or BoNTs) and treatment with each agent were compared using one-way ANOVA and Tukey's multiple comparison test. effects of perfusion with 10 M forskolin on the K ϩ -evoked serotonin release were reduced by perfusion with 0.1 M CCPA ( p Ͻ 0.05) and 10 M DMPX ( p Ͻ 0.05) (Fig. 13B) .
DISCUSSION
Mechanisms of hippocampal serotonin release
This study demonstrated that hippocampal basal and K ϩ -evoked serotonin releases require specific mechanisms for exocytosis. The basal serotonin release was regulated by N-VSCC, PKC, and syntaxin predominantly and by P-VSCC, PKA, and synaptobrevin weakly. In contrast to the basal release, K ϩ -evoked serotonin release was regulated by P-VSCC, PKA, and synaptobrevin predominantly, but by N-VSCC, PKC, and syntaxin weakly. In addition, the stimulatory effect of the PKC activator on basal serotonin release was more strongly inhibited by GVIA and BoNT/C than by IVA and BoNT/B, respectively. The stimulatory effect of an adenylate cyclase activator (forskolin) on basal serotonin release was more strongly inhibited by IVA and BoNT/B than by GVIA and BoNT/C, respectively. In contrast, the stimulatory effect of PKC activator on K ϩ -evoked serotonin release was more strongly inhibited by GVIA and BoNT/C than by IVA and BoNT/B, respectively. The stimulatory effect of adenylate cyclase activator on K ϩ -evoked serotonin release was more strongly inhibited by IVA and BoNT/B than by GVIA and BoNT/C, respectively. Therefore, the present study proves the existence of two major functional complexes for hippocampal serotonin release; the first is the N-VSCC/PKC/syntaxin pathway, which is the major pathway for basal serotonin release, and the other is the P-VSCC/PKA/ synaptobrevin pathway, which is the major pathway for K ϩ -evoked serotonin release.
Mechanisms of N-type VSCC-related exocytosis
Several electrophysiological experiments have demonstrated that P-VSCC is present in high density at central synapses and transmitter release primarily requires P-VSCC, with N-VSCC playing a secondary role (Luebke et al., 1993; Takahashi and Momiyama, 1993; Wheeler et al., 1994) . However, this study demonstrated that the basal hippocampal serotonin release required the N-VSCC/ PKC/syntaxin pathway predominantly.
Interaction of the synaptic protein interaction (synprint) site of N-VSCC with syntaxin and SNAP-25 has a biphasic Ca 2ϩ dependence with maximal binding at a range of 10 -30 M Ca 2ϩ , which is near the threshold for neurotransmitter release (Sheng et al., 1996; Kim and Catterall, 1997) . This interaction is regulated by PKC but not PKA Turner et al., 1999 1996). The synprint site of N-VSCC binds the dimetric complex of syntaxin/SNAP-25 and the trimetric complex syntaxin/SNAP-25/synaptobrevin in a Ca 2ϩ -dependent manner, with strongest binding in 4 -18 M Ca 2ϩ (Sheng et al., 1996) . The synprint site of N-VSCC and synaptotagmin competitively interacts with syntaxin . However, maximum binding of syntaxin to synaptotagmin requires a higher concentration of Ca 2ϩ in the range of 100 M[en]1 mM (Chapman et al., 1995; Li et al., 1995) . When the Ca 2ϩ concentration increases beyond 30 M, the interaction of syntaxin with the synprint site of N-VSCC is weakened, and interaction with synaptotagmin is strengthened. These previous observations can explain how the mechanisms of the basal hippocampal serotonin release are regulated by the N-VSCC/PKC/syntaxin pathway.
Mechanisms of P-type VSCC-related exocytosis
The ␣ 1A subunit of P-VSCC exists in two isoforms, designated rbA and BI when they were initially cloned (Mori et al., 1991; Starr et al., 1991) . Binding of the synprint peptide from the rbA and BI isoforms of the P-VSCC shows different dependencies on Ca 2ϩ concentration from the synprint site of N-VSCC (Kim and Catterall, 1997) . The BI isoform binds to syntaxin, SNAP-25, and synaptotagmin Ca 2ϩ independently. By contrast, the rbA isoform binds to synaptotagmin Ca 2ϩ dependently and to independently, but it does not bind to syntaxin. The interaction between synaptobrevin, which does not bind to synaptotagmin (Schiavo et al., 1997) , and P-VSCC has not been clarified; how- ever, the cleavage of synaptobrevin decreased K ϩ -evoked dopamine release but did not affect the dopamine release evoked by Ca 2ϩ ionophore ionomycin using rat brain synaptosomes (Fassio et al., 1999) . In our previous study (Okada et al., 1998a) , the basal striatal dopamine release was also regulated by N-VSCC predominantly; however, the K ϩ -evoked striatal dopamine release was regulated by P-VSCC predominantly. This previous evidence, taken together with the present results, therefore suggests that the requirements for neurotransmitter release of the depolarization and the spontaneous stage mechanisms may be different. Furthermore, the depolarization-induced neurotransmitter release requires an unknown Ca 2ϩ -dependent process or some other influence such as synaptic membrane phosphorylation induced by depolarization (Sheng et al., 1998; Turner et al., 1999) . Therefore, for an activation of the P-VSCC/PKA/synaptobrevin pathway, the synaptic membrane phosphorylation induced by depolarization or an unknown Ca 2ϩ -dependent process may be needed.
Effect of interaction between AD-R subtypes and synprint site on hippocampal basal serotonin release
This study demonstrated that the hippocampal basal serotonin release, which was N-VSCC/PKC/syntaxin high-sensitive and P-VSCC/PKA/synaptobrevin low-sensitive, was reduced by A1-R but was not affected by A2-R. The stimulatory effects of the PKC activator, PMA, and the adenylate cyclase activator, forskolin, on basal serotonin release were inhibited by the A1-R agonist, CCPA. The stimulatory effect of the A1-R antagonist, CPT, on basal serotonin release was inhibited by GVIA, CHR, and BoNT/C drastically, and H-89 and BoNT/B weakly, but was not affected by IVA. These results indicate that an activation of A1-R inhibits the N-VSCC/PKC/syntaxin pathway drastically, whereas A1-R inhib- its actions of both PKA and synaptobrevin without affecting P-VSCC activity.
Under the condition of A1-R blockade, an activation of A2-R increased the basal serotonin release. The stimulatory effect of the A2-R agonist, PD125944, was inhibited by IVA, H-89, and BoNT/B drastically, and by GVIA, CHR, and BoNT/C weakly. Moreover, under the condition of A1-R being functional, activation of adenylate cyclase activity produced the inhibitory effect of the A2-R antagonist and the stimulatory effect of the A2-R agonist on the basal serotonin release. These results indicate that the PKA activity plays an important role in the mechanisms of A2-R synaptic modulation. Therefore, the inhibition of PKA activity induced by endogenous adenosine via A1-R may be the major mechanism for abolishment of the stimulatory effect of A2-R on basal serotonin release.
Effect of interaction between AD-R subtypes and synprint site on hippocampal K
؉ -evoked serotonin release
The hippocampal K ϩ -evoked serotonin release, which was N-VSCC/PKC/syntaxin low-sensitive and P-VSCC/PKA/synaptobrevin high-sensitive, was modulated by both A1-R and A2-R because the K ϩ -evoked serotonin release was inhibited by CCPA and DMPX and enhanced by CPT and PD125944. Stimulatory effects of both CPT and PD125944 on K ϩ -evoked serotonin release were inhibited by IVA, H-89, and BoNT/B predominantly, and by GVIA, CHR, and BoNT/C weakly. The stimulatory effect of forskolin on K ϩ -evoked serotonin release was inhibited by both CCPA and DMPX. These results indicate that an activation of A1-R inhibits both the N-VSCC/PKC/syntaxin and P-VSCC/ PKA/synaptobrevin pathways. A2-R affects the P-VSCC/PKA/ synaptobrevin pathway more than the N-VSCC/PKC/syntaxin pathway.
Effect of interaction between A1-R and A2-R on hippocampal serotonin release
Colocalization and coexpression of mRNA encoding for A1-R and A2-R are found in hippocampus (Chuha et al., 1994) . The present study suggests that there are multiple forms of functional interaction between these receptor subtypes so that the excitatory responses of A2-R on hippocampal basal and K ϩ -evoked serotonin release were observed in the presence and absence, respectively, of A1-R antagonist conditions. This indicates that there is cross talk between A1-R and A2-R in the hippocampus and suggests that A2-R-mediated actions may be attenuated if these are concomitant activations of A1-R by endogenous adenosine via inhibition of PKA activity. The A2-R mediates attenuation of A1-R-mediated actions (Chuha et al., 1994) , and A1-R-mediated inhibition of A2-R actions has been suggested (Abbracchio et al., 1992) on the grounds that A1-R desensitization is accompanied by a time-dependent amplification of A2-R-mediated stimulation of adenylate cyclase activity (Ribeiro, 1999) . Furthermore, the excitatory response of A2-R is increased in the presence of A1-R antagonists (Correia-de-Sa and Ribeiro, 1994) . However, these previous findings can explain the interaction between A1-R and A2-R on basal serotonin release partially but not fully because the interaction must be mediated by the activities of presynaptic N-VSCC/PKC/syntaxin and P-VSCC/PKA/synaptobrevin pathways.
Conclusion
In this study, we showed that hippocampal serotonin release is composed of at least two types of processes, N-VSCC/PKC/ syntaxin high-sensitive and P-VSCC/PKA/synaptobrevin lowsensitive basal release (spontaneous release), as well as N-VSCC/ PKC/syntaxin low-sensitive and P-VSCC/PKA/synaptobrevin high-sensitive K ϩ -evoked release (depolarization-related release). An activation of A1-R inhibits both N-VSCC/PKC/syntaxin and P-VSCC/PKA/synaptobrevin activities, resulting in reduction of both basal and K ϩ -evoked serotonin releases. In contrast, an activation of A2-R enhances P-VSCC/PKA/synaptobrevin, resulting in elevation of basal serotonin release, under the condition of preventing the inhibition of PKA activity by A1-R. An activation of A2-R produces the enhancement of K ϩ -evoked serotonin release, under the condition of A1-R being functional, via an activation of PKA induced by K ϩ -evoked stimulation. Thus, this study suggests that the interaction between A2-R-mediated potentiation of P-VSCC/PKA/synaptobrevin and A1-R-mediated attenuation of N-VSCC/PKC/syntaxin plays an important role in hippocampal serotonergic transmission, and the stimulatory effects of A2-R on basal serotonin release may be masked by the inhibition of PKA induced by activation of A1-R. 
